NADP+-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance

Molecular Cell

Volumn 60, Issue 4, 2015, Pages 661-675

  Li, Feng ^a,d   He, Xiadi ^a,b,d   Ye, Dingwei ^a,c   Lin, Yan ^a,d   Yu, Hongxiu ^a   Yao, Cuifang ^a   Huang, Lei ^a,b   Zhang, Jianong ^a,b   Wang, Fang ^a   Xu, Sha ^a   Wu, Xiaohui ^a   Liu, Lixia ^e   Yang, Chen ^e   Shi, Jiaqi ^f   He, Xiaoyang ^g   Liu, Jie ^a,f   Qu, Yuanyuan ^a,c   Guo, Fushen ^a,b   Zhao, Jianyuan ^a,b   Xu, Wei ^a,d   Zhao, Shimin ^a,b,d   more..

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d SICHUAN UNIVERSITY   (China)

^e INSTITUTE OF PLANT PHYSIOLOGY AND ECOLOGY   (China)

^f GUIZHOU MEDICAL UNIVERSITY   (China)

^g Guizhou Cancer Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; GLYCINE; ISOCITRATE DEHYDROGENASE (NADP); ISOCITRATE DEHYDROGENASE 1; PROTEIN BCL 2; SIRTUIN 5; SUCCINATE DEHYDROGENASE; SUCCINYL COENZYME A; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; SUCCINIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL MEMBRANE DEPOLARIZATION; CELL METABOLISM; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE MUTATION; GLIOMA; HUMAN; HUMAN CELL; HYPERSUCCINYLATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN AGGREGATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; GENETICS; HEK293 CELL LINE; METABOLISM; MITOCHONDRION; MUTATION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; GLUTARATES; HEK293 CELLS; HUMANS; ISOCITRATE DEHYDROGENASE; MICE; MITOCHONDRIA; MUTATION; NEOPLASMS, EXPERIMENTAL; SUCCINATE DEHYDROGENASE; SUCCINIC ACID;

EID: 84947745877     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2015.10.017     Document Type: Article

References (55)

1. Adam J., Hatipoglu E., O'Flaherty L., Ternette N., Sahgal N., Lockstone H., Baban D., Nye E., Stamp G.W., Wolhuter K., et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011, 20:524-537.
2. Amary M.F., Bacsi K., Maggiani F., Damato S., Halai D., Berisha F., Pollock R., O'Donnell P., Grigoriadis A., Diss T., et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 2011, 224:334-343.
3. Bennett B.D., Kimball E.H., Gao M., Osterhout R., Van Dien S.J., Rabinowitz J.D. Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nat. Chem. Biol. 2009, 5:593-599.
4. Blom H.J., Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J. Inherit. Metab. Dis. 2011, 34:75-81.
5. Chan S.M., Thomas D., Corces-Zimmerman M.R., Xavy S., Rastogi S., Hong W.J., Zhao F., Medeiros B.C., Tyvoll D.A., Majeti R. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 2015, 21:178-184.
6. Christensen B.C., Smith A.A., Zheng S., Koestler D.C., Houseman E.A., Marsit C.J., Wiemels J.L., Nelson H.H., Karagas M.R., Wrensch M.R., et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl. Cancer Inst. 2011, 103:143-153.
7. Colak G., Xie Z., Zhu A.Y., Dai L., Lu Z., Zhang Y., Wan X., Chen Y., Cha Y.H., Lin H., et al. Identification of lysine succinylation substrates and the succinylation regulatory enzyme CobB in Escherichia coli. Mol. Cell. Proteomics 2013, 12:3509-3520.
8. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
9. Dawson S.J., Makretsov N., Blows F.M., Driver K.E., Provenzano E., Le Quesne J., Baglietto L., Severi G., Giles G.G., McLean C.A., et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br. J. Cancer 2010, 103:668-675.
10. Du J., Zhou Y., Su X., Yu J.J., Khan S., Jiang H., Kim J., Woo J., Kim J.H., Choi B.H., et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 2011, 334:806-809.
11. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
12. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389:349-352.
13. Harris M.H., Thompson C.B. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 2000, 7:1182-1191.
14. Herod J.J., Eliopoulos A.G., Warwick J., Niedobitek G., Young L.S., Kerr D.J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 1996, 56:2178-2184.
15. Hirschey M.D., Shimazu T., Goetzman E., Jing E., Schwer B., Lombard D.B., Grueter C.A., Harris C., Biddinger S., Ilkayeva O.R., et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010, 464:121-125.
16. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2:277-288.
17. Isaacs J.S., Jung Y.J., Mole D.R., Lee S., Torres-Cabala C., Chung Y.L., Merino M., Trepel J., Zbar B., Toro J., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005, 8:143-153.
18. Jaberi E., Chitsazian F., Ali Shahidi G., Rohani M., Sina F., Safari I., Malakouti Nejad M., Houshmand M., Klotzle B., Elahi E. The novel mutation p.Asp251Asn in the β-subunit of succinate-CoA ligase causes encephalomyopathy and elevated succinylcarnitine. J. Hum. Genet. 2013, 58:526-530.
19. Jakubowski H., Zhang L., Bardeguez A., Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ. Res. 2000, 87:45-51.
20. Jin G., Pirozzi C.J., Chen L.H., Lopez G.Y., Duncan C.G., Feng J., Spasojevic I., Bigner D.D., He Y., Yan H. Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget 2012, 3:774-782.
21. Killian J.K., Kim S.Y., Miettinen M., Smith C., Merino M., Tsokos M., Quezado M., Smith W.I., Jahromi M.S., Xekouki P., et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013, 3:648-657.
22. Koivunen P., Lee S., Duncan C.G., Lopez G., Lu G., Ramkissoon S., Losman J.A., Joensuu P., Bergmann U., Gross S., et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012, 483:484-488.
23. Lai C.C., Lin P.M., Lin S.F., Hsu C.H., Lin H.C., Hu M.L., Hsu C.M., Yang M.Y. Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol. 2013, 34:1847-1854.
24. Lemire B.D., Oyedotun K.S. The Saccharomyces cerevisiae mitochondrial succinate:ubiquinone oxidoreductase. Biochim. Biophys. Acta 2002, 1553:102-116.
25. Letouzé E., Martinelli C., Loriot C., Burnichon N., Abermil N., Ottolenghi C., Janin M., Menara M., Nguyen A.T., Benit P., et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013, 23:739-752.
26. Li F., Xu W., Zhao S. Regulatory roles of metabolites in cell signaling networks. J. Genet. Genomics 2013, 40:367-374.
27. Lin Z.F., Xu H.B., Wang J.Y., Lin Q., Ruan Z., Liu F.B., Jin W., Huang H.H., Chen X. SIRT5 desuccinylates and activates SOD1 to eliminate ROS. Biochem. Biophys. Res. Commun. 2013, 441:191-195.
28. Losman J.A., Looper R.E., Koivunen P., Lee S., Schneider R.K., McMahon C., Cowley G.S., Root D.E., Ebert B.L., Kaelin W.G. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339:1621-1625.
29. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., Edwards C.R., Khanin R., Figueroa M.E., Melnick A., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
30. Lu W., Zuo Y., Feng Y., Zhang M. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. Tumour Biol. 2014, 35:10699-10705.
31. Ma S., Jiang B., Deng W., Gu Z.-K., Wu F.-Z., Li T., Xia Y., Yang H., Ye D., Xiong Y., Guan K.L. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. Oncotarget 2015, 6:8606-8620.
32. Maloyan A., Sanbe A., Osinska H., Westfall M., Robinson D., Imahashi K., Murphy E., Robbins J. Mitochondrial dysfunction and apoptosis underlie the pathogenic process in alpha-B-crystallin desmin-related cardiomyopathy. Circulation 2005, 112:3451-3461.
33. Nelson D.L., Cox M.M. Lehninger Principles of Biochimestry 2008, Freeman.
34. Nishida Y., Rardin M.J., Carrico C., He W., Sahu A.K., Gut P., Najjar R., Fitch M., Hellerstein M., Gibson B.W., Verdin E. SIRT5 regulates both cytosolic and mitochondrial protein malonylation with glycolysis as a major target. Mol. Cell 2015, 59:321-332.
35. Ogura R., Tsukamoto Y., Natsumeda M., Isogawa M., Aoki H., Kobayashi T., Yoshida S., Okamoto K., Takahashi H., Fujii Y., Kakita A. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas. Neuropathology 2015, 35:324-335.
36. Ooi A., Wong J.C., Petillo D., Roossien D., Perrier-Trudova V., Whitten D., Min B.W.H., Tan M.H., Zhang Z., Yang X.J., et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011, 20:511-523.
37. Park J., Chen Y., Tishkoff D.X., Peng C., Tan M., Dai L., Xie Z., Zhang Y., Zwaans B.M., Skinner M.E., et al. SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol. Cell 2013, 50:919-930.
38. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
39. Rardin M.J., He W., Nishida Y., Newman J.C., Carrico C., Danielson S.R., Guo A., Gut P., Sahu A.K., Li B., et al. SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab. 2013, 18:920-933.
40. Rohle D., Popovici-Muller J., Palaskas N., Turcan S., Grommes C., Campos C., Tsoi J., Clark O., Oldrini B., Komisopoulou E., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340:626-630.
41. Sabha N., Knobbe C.B., Maganti M., Al Omar S., Bernstein M., Cairns R., Çako B., von Deimling A., Capper D., Mak T.W., et al. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro-oncol. 2014, 16:914-923.
42. Sanson M., Marie Y., Paris S., Idbaih A., Laffaire J., Ducray F., El Hallani S., Boisselier B., Mokhtari K., Hoang-Xuan K., Delattre J.Y. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 2009, 27:4150-4154.
43. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7:77-85.
44. Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., Campos C., Fabius A.W., Lu C., Ward P.S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
45. Wagner G.R., Payne R.M. Widespread and enzyme-independent Nε-acetylation and Nε-succinylation of proteins in the chemical conditions of the mitochondrial matrix. J. Biol. Chem. 2013, 288:29036-29045.
46. Wang P., Dong Q., Zhang C., Kuan P.F., Liu Y., Jeck W.R., Andersen J.B., Jiang W., Savich G.L., Tan T.X., et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2013, 32:3091-3100.
47. Weinert B.T., Schölz C., Wagner S.A., Iesmantavicius V., Su D., Daniel J.A., Choudhary C. Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep. 2013, 4:842-851.
48. Xiao M., Yang H., Xu W., Ma S., Lin H., Zhu H., Liu L., Liu Y., Yang C., Xu Y., et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012, 26:1326-1338.
49. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Wang P., Xiao M.T., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
50. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
51. Zamzami N., Susin S.A., Marchetti P., Hirsch T., Gómez-Monterrey I., Castedo M., Kroemer G. Mitochondrial control of nuclear apoptosis. J. Exp. Med. 1996, 183:1533-1544.
52. Zhang Z., Tan M., Xie Z., Dai L., Chen Y., Zhao Y. Identification of lysine succinylation as a new post-translational modification. Nat. Chem. Biol. 2011, 7:58-63.
53. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong L., Peng Y., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261-265.
54. Zhao S., Xu W., Jiang W., Yu W., Lin Y., Zhang T., Yao J., Zhou L., Zeng Y., Li H., et al. Regulation of cellular metabolism by protein lysine acetylation. Science 2010, 327:1000-1004.
55. Zinn A.B., Kerr D.S., Hoppel C.L. Fumarase deficiency: a new cause of mitochondrial encephalomyopathy. N. Engl. J. Med. 1986, 315:469-475.